Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1950 of 2228 entries
View as:

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase: N/A Priority: Normal
NCT ID: NCT00748709 Org: User:
Start: 10/01/08 End: - Due: -

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03099174 Org: User:
Start: 05/04/17 End: 05/16/24 Due: 05/16/25

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Phase: N/A Priority: Normal
NCT ID: NCT03964233 Org: User:
Start: 06/20/19 End: 05/30/26 Due: 05/30/27

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Phase: N/A Priority: Normal
NCT ID: NCT03886246 Org: User:
Start: 05/29/19 End: 04/27/28 Due: 04/27/29

Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)

Phase: N/A Priority: Normal
NCT ID: NCT04402515 Org: User:
Start: 10/28/21 End: 01/31/22 Due: 01/31/23

A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06984926 Org: User:
Start: 06/06/25 End: 03/09/26 Due: 03/09/27

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Phase: N/A Priority: Normal
NCT ID: NCT07001475 Org: User:
Start: 07/04/25 End: 05/27/26 Due: 05/27/27

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02215031 Org: User:
Start: 09/30/08 End: - Due: -

A Study in Healthy People to Compare Two Different Sifrol® Tablets

Phase: N/A Priority: Normal
NCT ID: NCT06457204 Org: User:
Start: 06/27/24 End: 08/12/24 Due: 08/12/25

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Phase: N/A Priority: Normal
NCT ID: NCT03057977 Org: User:
Start: 03/06/17 End: 05/28/20 Due: 05/28/21

Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01146886 Org: User:
Start: 06/30/10 End: - Due: -

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Phase: N/A Priority: Normal
NCT ID: NCT02170792 Org: User:
Start: 02/28/01 End: - Due: -

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02183701 Org: User:
Start: 04/30/98 End: - Due: -

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01559116 Org: User:
Start: 03/31/12 End: 08/31/13 Due: 08/31/14

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

Phase: N/A Priority: Normal
NCT ID: NCT01458886 Org: User:
Start: 11/30/11 End: - Due: -

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02123823 Org: User:
Start: 05/15/14 End: 12/14/21 Due: 12/14/22

A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food

Phase: N/A Priority: Normal
NCT ID: NCT04789291 Org: User:
Start: 05/18/21 End: 08/07/21 Due: 08/07/22

Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02171013 Org: User:
Start: 04/30/06 End: - Due: -

Real World Data on Gi(l)Otrif® Dose Adjustment

Phase: N/A Priority: Normal
NCT ID: NCT02751879 Org: User:
Start: 11/24/16 End: 09/30/17 Due: 09/30/18

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

Phase: N/A Priority: Normal
NCT ID: NCT02198339 Org: User:
Start: 02/28/99 End: - Due: -

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02245438 Org: User:
Start: 05/31/02 End: - Due: -

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Phase: N/A Priority: Normal
NCT ID: NCT06655220 Org: User:
Start: 11/08/24 End: 01/13/25 Due: 01/13/26

Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02170675 Org: User:
Start: 06/30/09 End: - Due: -

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women

Phase: N/A Priority: Normal
NCT ID: NCT02182791 Org: User:
Start: 04/30/98 End: - Due: -

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Phase: N/A Priority: Normal
NCT ID: NCT05934955 Org: User:
Start: 07/13/23 End: 10/02/23 Due: 10/02/24